CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies using their PROBODY and Veloci-Bi platforms. CytomX will receive a $37 million payment for two new targets, with Regeneron having options for up to six additional targets. This partnership aims to create safer, more effective immunotherapies by activating treatments only in the tumor environment, potentially improving outcomes for difficult-to-treat cancers. The deal could generate up to $4 billion in milestones and royalties for CytomX as the programs advance through development and commercialization.
Regeneron Pharmaceuticals announced it will present new clinical data and research on treatments for metabolic diseases, eye conditions, and rare diseases at the ADA and ENDO medical meetings in June 2026. Highlights include Phase 2 trial results on ...
Pomerantz LLP is investigating Regeneron Pharmaceuticals for potential securities fraud after the company announced that its Phase 3 trial for a melanoma drug combo failed to meet key goals. The news caused Regeneron's stock to drop nearly 10%. The i...
